Impax Laboratories, Inc. (NASDAQ:IPXL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
scheduled to present at the 35th Annual J.P. Morgan Healthcare
Conference. A copy of the materials that the Company will present
at the conference is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
7.01 hereof will not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), nor will it be deemed to be incorporated by
reference into any filing under the Securities Act of 1933, as
amended, or the Exchange Act unless expressly identified therein
as being specifically incorporated therein by reference.
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
35th Annual J.P. Morgan Healthcare Conference
Presentation dated as of January 11, 2017. |
About Impax Laboratories, Inc. (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches. Impax Laboratories, Inc. (NASDAQ:IPXL) Recent Trading Information
Impax Laboratories, Inc. (NASDAQ:IPXL) closed its last trading session 00.00 at 12.70 with 1,788,430 shares trading hands.
